Literature DB >> 9379195

PET scanning and the human immunodeficiency virus-positive patient.

M J O'Doherty1, S F Barrington, M Campbell, J Lowe, C S Bradbeer.   

Abstract

UNLABELLED: The use of PET scanning in patients with human immunodeficiency virus infection and fever of unknown origin, confusion and/or weight loss was investigated.
METHODS: Eighty patients were examined using PET. Fifty-seven patients had half-body scans with [18F]fluorodeoxyglucose (FDG), and 23 patients had brain studies performed with FDG. Fourteen patients also had [11C]methionine studies (2 chest, 1 abdomen and 11 brain) performed.
RESULTS: Thirteen patients with lymphoma had the extent of the disease clearly identified in both nodal and extranodal sites. Patients with a variety of infections (Cryptococcus neoformans, Pseudomonas aeruginosa, Mycobacterium tuberculosis and Mycobacterium avium intracellulare) had disease localized for appropriate biopsy or sampling procedures. A half-body FDG-PET scan had a sensitivity of 92% and a specificity of 94% for localization of focal pathology that needed treatment. High uptake of FDG (greater than liver) had a positive predictive value for pathology needing treatment of 95%. FDG brain studies showed that 16 patients with CD4 T-lymphocyte counts less than 200 cells/ml had reduced cortical uptake compared with that in basal ganglia. FDG scans were abnormal in all 19 patients with focal space occupying lesions identified by magnetic resonance scans. The standardized uptake values (SUVs) over cerebral lesions due to toxoplasma were in the range of 0.14-3.7 (13 patients) and due to lymphoma were in the range of 3.9-8.7 (6 patients). Three more patients with progressive multifocal leukoencephalopathy had SUVs in the range of 1.0-1.5 over the lesions. Another patient had a low-grade oligodendroglioma (SUV = 2.9). Carbon-11-methionine uptake also was high in patients with cerebral lymphoma but did not add to the discrimination between toxoplasmosis and lymphoma in these patients obtained with the FDG scan.
CONCLUSION: In hospitals with access to PET facilities, FDG scanning allows the rapid evaluation of the whole body, including the brain, of patients with human immunodeficiency virus infection, with a report potentially available within 4 hr of injection. Sites of infection and tumor were identified, and discrimination between cerebral pathologies was possible.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9379195

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  41 in total

1.  FDG-PET in infectious and inflammatory disease.

Authors:  J Buscombe; A Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-02       Impact factor: 9.236

Review 2.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

3.  18FDG-PET for monitoring disease activity in an HIV-1 positive patient with disseminated chronic osteomyelitic brucellosis due to Brucella melitensis.

Authors:  John J Zaknun; Robert Zangerle; Michael Gabriel; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

4.  FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.

Authors:  H Palmedo; H Urbach; H Bender; U Schlegel; I G H Schmidt-Wolf; A Matthies; M Linnebank; A Joe; J Bucerius; H-J Biersack; H Pels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-12       Impact factor: 9.236

5.  Delayed [(18)F]FDG PET imaging of central nervous system lymphoma: is PET better than MRI?

Authors:  Christian Jeanguillaume; Gilles Metrard; Hervé Rakotonirina; Olivier Morel; Cécile Berthelot; Tanguy Blaire; Francis Bouchet; Sylvie Giraud; Franck Lacoeuille; Aurélie Cahouet; Malgorzata Truchan-Graczyk; Charles Foussard; Jean Jacques Lejeune
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-19       Impact factor: 9.236

6.  FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease.

Authors:  Rob Barker; Fahrad Kazmi; Justin Stebbing; Sarah Ngan; Roger Chinn; Mark Nelson; Michael O'Doherty; Mark Bower
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-03       Impact factor: 9.236

7.  Molecular medicine successes in neuroscience.

Authors:  Bernhard Schaller; Jan F Cornelius; Nora Sandu
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

8.  Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS.

Authors:  R F Miller; M A Hall-Craggs; D C Costa; N S Brink; F Scaravilli; S B Lucas; I D Wilkinson; P J Ell; B E Kendall; M J Harrison
Journal:  Sex Transm Infect       Date:  1998-08       Impact factor: 3.519

Review 9.  Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rakesh Kumar; Sandip Basu; Drew Torigian; Vivek Anand; Hongming Zhuang; Abass Alavi
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

10.  Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry.

Authors:  Joyce C Mhlanga; Daniel Durand; Hua-Ling Tsai; Christine M Durand; Jeffrey P Leal; Hao Wang; Richard Moore; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.